Published in Am J Transplant on June 30, 2011
Immunosuppression, generic drugs and the FDA. Am J Transplant (2011) 2.43
Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. BMJ (2015) 1.49
A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant (2012) 1.11
Systematic conversion to generic tacrolimus in stable kidney transplant recipients. Clin Kidney J (2014) 0.96
The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. Appl Health Econ Health Policy (2015) 0.92
Is it ethical to prescribe generic immunosuppressive drugs to renal transplant patients? Can J Kidney Health Dis (2014) 0.82
Progress in abdominal organ transplantation. Med Sci Monit (2011) 0.81
Equivalence and interchangeability of narrow therapeutic index drugs in organ transplantation. Eur J Hosp Pharm Sci Pract (2013) 0.81
Transplant coordinators' perceived impact of availability of multiple generic immunosuppression therapies on patients, workload, and posttransplant maintenance therapy. J Transplant (2013) 0.78
Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. Transpl Int (2012) 0.77
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod. Drug Des Devel Ther (2016) 0.75
Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan(®) and Mowel(®) after liver transplantation. Drug Des Devel Ther (2015) 0.75
Switching Stable Kidney Transplant Recipients to a Generic Tacrolimus Is Feasible and Safe, but It Must Be Monitored. J Transplant (2017) 0.75
A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation. Ther Drug Monit (2017) 0.75
Comparison of the long-term efficacy and safety of generic Tacrobell with original tacrolimus (Prograf) in kidney transplant recipients. Drug Des Devel Ther (2017) 0.75
Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients. Pediatr Nephrol (2017) 0.75
Impact of Conversion From Advagraf to Twice-Daily Generic Tacrolimus in Kidney Transplant Recipients: A Single-Center Study-A 3-Year Follow-Up. Transplant Direct (2017) 0.75
Kidney transplantation under FK 506. JAMA (1990) 7.45
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Nucleic acid reactivity and conformation. II. Reaction of cytosine and uracil with sodium bisulfite. J Biol Chem (1973) 4.44
X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet (2001) 3.86
The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet (1986) 3.53
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant (2007) 3.02
Deamination of cytosine derivatives by bisulfite. Mechanism of the reaction. J Am Chem Soc (1974) 2.92
Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant (2010) 2.66
Medical education and health for all. Aust J Public Health (1995) 2.65
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther (1985) 2.38
The deamination of cytidine and cytosine by acidic buffer solutions. Mutagenic implications. Biochemistry (1966) 2.30
Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J (1999) 2.28
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
On the reaction of guanine with glyoxal, pyruvaldehyde, and kethoxal, and the structure of the acylguanines. A new synthesis of N2-alkylguanines. Biochemistry (1969) 2.25
Immunologic and nonimmunologic factors: different risks for cadaver and living donor transplantation. Transplantation (2000) 2.25
Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant (2009) 2.25
Overview: deinstitutionalization of psychiatric patients, a critical review of outcome studies. Am J Psychiatry (1981) 2.24
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol (1988) 2.21
A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant (2010) 2.14
American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant (2006) 2.11
Characteristic ribonucleolytic activity of human angiogenin. Biochemistry (1986) 2.06
Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant (2014) 2.00
Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation (1999) 1.93
Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg (2001) 1.89
The point system for organ distribution. Transplant Proc (1989) 1.88
Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83
Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution. EMBO J (1997) 1.77
Specific acylation of the guanine residues of ribonucleic acid. J Biol Chem (1970) 1.74
Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm (1995) 1.69
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem (2001) 1.67
Long-term follow-up of living kidney donors: quality of life after donation. Transplantation (1999) 1.65
Cryoablation of unresectable malignant liver tumors. Am J Surg (1996) 1.62
Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis (1985) 1.61
Donor-transmitted malignancies in organ transplantation: assessment of clinical risk. Am J Transplant (2011) 1.59
Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol (1992) 1.58
The 'two, one, zero' decision: what to do with suboptimal deceased donor kidneys. Am J Transplant (2010) 1.58
Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant (2013) 1.58
Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor. Biochemistry (1989) 1.57
Sites of nonenzymatic glycosylation of human hemoglobin A. J Biol Chem (1980) 1.56
New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc (1991) 1.56
Regular articles: conditional disruption of hedgehog signaling pathway defines its critical role in hair development and regeneration. J Invest Dermatol (2000) 1.56
Cyclosporine Monitoring and Pharmacokinetics in Pediatrie Liver Transplant Patients. Transplant Proc (1985) 1.55
Comparison of FK-506 and cyclosporine regimens in pediatric renal transplantation. Pediatr Nephrol (1994) 1.55
Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant (2012) 1.55
Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Proc Natl Acad Sci U S A (1987) 1.55
Acidic hydrolysis of deoxycytidine and deoxyuridine derivatives. The general mechanism of deoxyribonucleoside hydrolysis. Biochemistry (1972) 1.54
Nosocomial outbreak of tuberculosis in a renal transplant unit: application of a new technique for restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates. J Infect Dis (1993) 1.53
Posterior reversible encephalopathy syndrome after solid organ transplantation. AJNR Am J Neuroradiol (2008) 1.53
"Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. Am J Transplant (2013) 1.52
Bisulfite-catalyzed transamination of cytosine and cytidine. Biochem Biophys Res Commun (1970) 1.52
Isolation and identification of cross-links from formaldehyde-treated nucleic acids. Biochemistry (1980) 1.52
Ethical considerations for participation of nondirected living donors in kidney exchange programs. Am J Transplant (2010) 1.51
The reaction of guanine derivatives with 1,2-dicarbonyl compounds. Biochemistry (1966) 1.50
Uncatalyzed hydrolysis of deoxyuridine, thymidine, and 5-bromodeoxyuridine. Biochemistry (1969) 1.49
Pancreas transplantation with enteric drainage under tacrolimus induction therapy. Transplant Proc (1997) 1.48
The mutagenic specificity of sodium bisulfite. Biochem Biophys Res Commun (1970) 1.48
Cytomegalovirus in solid organ transplantation. Am J Transplant (2013) 1.48
Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant (2007) 1.47
Fatal Falciparum malaria in Canadian travellers. Can Commun Dis Rep (1996) 1.46
Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol (1988) 1.45
Pharmacokinetics of orally administered ritodrine. Am J Obstet Gynecol (1989) 1.45
Selective retransplant after graft loss to nonadherence: success with a second chance. Am J Transplant (2009) 1.44
Crystal structure of the superantigen enterotoxin C2 from Staphylococcus aureus reveals a zinc-binding site. Structure (1995) 1.42
Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant (2009) 1.42
Adverse effects associated with the use of FK 506. Transplant Proc (1991) 1.41
2,500 living donor kidney transplants: a single-center experience. Ann Surg (2001) 1.41
Ciprofloxacin does not block the antiproliferative effect of tacrolimus. Transplantation (1997) 1.39
Mechanism of obstruction of the infradiaphragmatic portion of the inferior vena cava in the presence of increased intra-abdominal pressure. Invest Radiol (1966) 1.39
FK 506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc (1991) 1.37
Diffuse skeletal abnormalities in Forestier disease. Arch Intern Med (1976) 1.37
Embryogenesis of the human occipital bone. AJR Am J Roentgenol (1976) 1.36
Contribution of naïve and memory T-cell populations to the human alloimmune response. Am J Transplant (2009) 1.34
Assay of FK 506 in plasma. Transplant Proc (1990) 1.32
The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol (1993) 1.32
Two-year follow-up of the patients included in the WHO International Pilot Study of Schizophrenia. Psychol Med (1977) 1.32
Sensitivity of activated human lymphocytes to cyclosporine and its metabolites. Hum Immunol (1988) 1.31
Indomethacin-induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med (1979) 1.30
The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos (1999) 1.30
Structural heterogeneity of human hemoglobin A due to nonenzymatic glycosylation. J Biol Chem (1979) 1.30
Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci U S A (1994) 1.30
Dual site model for the organogenic activity of angiogenin. Proc Natl Acad Sci U S A (1991) 1.29
BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis (1995) 1.28
Excretion of cyclosporine and its metabolites in human bile. Transplant Proc (1986) 1.27
The Danish twin register. Acta Genet Med Gemellol (Roma) (1968) 1.25
Leukotriene A4 hydrolase: determination of the three zinc-binding ligands by site-directed mutagenesis and zinc analysis. Proc Natl Acad Sci U S A (1991) 1.25
Ovarian carcinomatosis presenting with hyperamylasemia and pleural effusion. Am J Gastroenterol (1981) 1.24
Role of bile and bile salts on cyclosporine absorption in dogs. Transplant Proc (1987) 1.24